Health Care Ruling Could Mean Years Of Delay For Biosimilars

By Rachel Slajda (June 14, 2012, 10:17 PM EDT) -- If the U.S. Supreme Court decides to strike down the entire health care law it could delay the debut of biosimilars onto the U.S. market for months or even years — along with their potential to cut billions of dollars from the country's total drug spending — especially if Congress devolves into partisan squabbling over re-enacting the biosimilars provisions. ...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!